Cancer research

The Leukemia & Lymphoma Society, The Mark Foundation for Cancer Research and The Paul G. Allen Frontiers Group Partner to Award $6.75M in New Grants to Drive the Next Wave of Novel Cancer Therapies

Wednesday, July 1, 2020 - 1:30pm

Each project will be supported by an award of $750,000 over a three-year period.

Key Points: 
  • Each project will be supported by an award of $750,000 over a three-year period.
  • "In science, collaboration can accelerate the pace of achievement," said Michele Cleary, Ph.D., CEO ofThe Mark Foundation for Cancer Research.
  • "We are grateful that the Frontiers Group and Mark Foundation have aligned with us to fund some of the greatest minds in cancer discovery," said LLS's Greenberger.
  • The Mark Foundation for Cancer Research actively partners with scientists to accelerate research that will transform the prevention, diagnosis, and treatment of cancer.

The American Cancer Society and Flatiron Health Announce Recipients of the Real-World Data Impact Award

Wednesday, July 1, 2020 - 1:32pm

Three American Cancer Society researchers will receive the Real-World Data Impact Award to advance patient-centric research, the ACS and Flatiron Health announced today.

Key Points: 
  • Three American Cancer Society researchers will receive the Real-World Data Impact Award to advance patient-centric research, the ACS and Flatiron Health announced today.
  • The joint grant-making program supports both organizations goals of accelerating cancer research and improving treatment and outcomes for patients.
  • The American Cancer Society is a global grassroots force of 1.5 million volunteers dedicated to saving lives, celebrating lives, and leading the fight for a world without cancer.
  • Flatiron Health is a healthcare technology and services company focused on accelerating cancer research and improving patient care.

REMAP-CAP to Partner With Eisai on Innovative Trial to Combat COVID

Wednesday, July 1, 2020 - 12:00am

The trial will be conducted in the multi-hospital UPMC health system along with other medical centers in the United States.

Key Points: 
  • The trial will be conducted in the multi-hospital UPMC health system along with other medical centers in the United States.
  • REMAP-COVID is an optimal study to identify potential treatments for COVID-19 as safely, quickly, and effectively as possible.
  • Eisai is proud to be part of this collaborative initiative to fight the unprecedented COVID-19 pandemic.
  • Most recently, the Breast Cancer Research Foundation, committed $1M to help launch U.S. trial sites through the long-established, innovative trial infrastructure of the Translational Breast Cancer Research Consortium.

Global Genomic Cancer Panel and Profiling Markets (2020 to 2024) - Featuring Agena Bioscience, Agilent & Almac Diagnostics Among Others - ResearchAndMarkets.com

Monday, June 29, 2020 - 3:53pm

The "Genomic Cancer Panel and Profiling Markets by Cancer and Germline/Somatic Type with Screening Potential Market Size, Customized Forecasting/Analysis, and Executive and Consultant Guides 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Genomic Cancer Panel and Profiling Markets by Cancer and Germline/Somatic Type with Screening Potential Market Size, Customized Forecasting/Analysis, and Executive and Consultant Guides 2020-2024" report has been added to ResearchAndMarkets.com's offering.
  • Cancer Gene Panels and Genomic Profiling are quickly changing the diagnosis and treatment of cancers.
  • The market is moving out of a specialized niche and going mainstream as Oncologists begin routinely using the information on the hundreds of genes related to cancer.
  • The market is exploding as physicians use all the information they can get in the battle against cancer.

iRECIST Criteria: An Operational Approach in Oncology Clinical Trials, Upcoming Webinar Hosted by Xtalks

Monday, June 29, 2020 - 1:30pm

Manager, Bioclinica in a live webinar on Thursday, July 16, 2020 at 11am EDT (4pm BST/UK).

Key Points: 
  • Manager, Bioclinica in a live webinar on Thursday, July 16, 2020 at 11am EDT (4pm BST/UK).
  • As immunotherapies continue to evolve, the assessment of disease progression can be challenging to distinguish from the immune response.
  • The goal of this webinar is to discuss an operational approach for using the iRECIST criteria in support of oncology clinical trials.
  • For more information or to register for this event, visit iRECIST Criteria: An Operational Approach in Oncology Clinical Trials .

miRagen Announces Encouraging Preclinical Safety and Efficacy Data for its Next-generation miR-29 Replacement Product Candidate Intended for the Treatment of Idiopathic Pulmonary Fibrosis

Monday, June 22, 2020 - 10:08pm

Next-generation targeted miR-29 mimics demonstrated target pathway down-regulation assessed by fibrotic gene signatures in normal human lung fibroblasts in vitro.

Key Points: 
  • Next-generation targeted miR-29 mimics demonstrated target pathway down-regulation assessed by fibrotic gene signatures in normal human lung fibroblasts in vitro.
  • Next-generation miR-29 mimics blocked fibrosis in a therapeutic dosing-regimen of mouse bleomycin-induced pulmonary fibrosis with increased potency compared to first generation miR-29 mimics.
  • Anti-fibrotic activity of next-generation miR-29 mimics in mouse bleomycin-induced pulmonary fibrosis was observed for both intravenous and subcutaneous routes of administration.
  • MRG-110, an inhibitor of miR-92, is miRagens product candidate for the treatment of heart failure and other ischemic disease.

50% Complete Response Rate Observed in YourVaccx™ Study for Patients with Metastatic Prostate Cancer was Presented at the AACR Virtual Annual Meeting II

Monday, June 22, 2020 - 2:00pm

The patients were assessed after the completion of therapy, which varied from between 1 and 3 cycles of treatment.

Key Points: 
  • The patients were assessed after the completion of therapy, which varied from between 1 and 3 cycles of treatment.
  • All responses to therapy were assessed by RECIST v. 1.1 and metastatic prostate cancer patients were also assessed by serum PSA levels.
  • For all evaluable patients, the PoC study data showed a 38% (9/24) complete response rate (CR) and a 4% (1/24) partial response rate (PR), for an objective response rate (ORR) of 42% (10/24).
  • is now available at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II.

ImmunoGen Presents Preclinical Data on IMGN151 at Virtual AACR Annual Meeting

Monday, June 22, 2020 - 2:01pm

The findings were shared via poster presentation at the virtual American Association for Cancer Research (AACR) Annual Meeting II.

Key Points: 
  • The findings were shared via poster presentation at the virtual American Association for Cancer Research (AACR) Annual Meeting II.
  • IMGN151 demonstrated enhanced anti-tumor activity in both in vitro and in vivo preclinical models, with complete regression of human tumor xenograft models induced in those with high, medium, and low levels of FR expression.
  • Based on these data, we look forward to exploring IMGN151 in the clinic in multiple FR-positive epithelial malignancies, including ovarian, endometrial, triple negative breast, and non-small cell lung cancer.
  • IMGN151 activity was characterized against cell lines and xenograft models with a wide range of FR expression and compared to mirvetuximab soravtansine (IMGN853).

Lung Cancer Research Foundation Names Dr. Trudy Oliver to its Scientific Advisory Board

Monday, June 22, 2020 - 1:00pm

NEW YORK, June 22, 2020 /PRNewswire/ --The Lung Cancer Research Foundation (LCRF) today announced that Dr. Trudy Oliver has joined its Scientific Advisory Board.

Key Points: 
  • NEW YORK, June 22, 2020 /PRNewswire/ --The Lung Cancer Research Foundation (LCRF) today announced that Dr. Trudy Oliver has joined its Scientific Advisory Board.
  • "I am excited to welcome Dr. Oliver to LCRF's Scientific Advisory Board and look forward to working with her to continue the Foundation's commitment to funding outstanding lung cancer research and investigators," said Dr. Katerina Politi, Chair of LCRF's Scientific Advisory Board.
  • LCRF's mission is to improve lung cancer outcomes by funding research for the prevention, diagnosis, treatment and cure of lung cancer.
  • In addition to funding lung cancer research, the organization focuses on lung cancer awareness and educational programs.

TYME Presents New Preclinical Data Supporting SM-88 Mechanism of Action at AACR 2020

Monday, June 22, 2020 - 1:00pm

TYME has initiated comprehensive in vitro and in vivo experimental studies that are designed to elucidate the mechanism of action and further characterize the anti-cancer effects of SM-88 as a standalone investigational compound.

Key Points: 
  • TYME has initiated comprehensive in vitro and in vivo experimental studies that are designed to elucidate the mechanism of action and further characterize the anti-cancer effects of SM-88 as a standalone investigational compound.
  • To further validate the anti-cancer effects of SM-88, a second in vivo study was conducted using a pancreatic cancer animal model (PAN02).
  • This process is utilized by cancer cells as a survival mechanism in periods when nutritional sources are low.
  • Details of this preclinical study were presented at the American Association for Cancer Research Virtual Meeting from June 22 to June 24, 2020.